Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVM-022 (Ixoberogene soroparvovec) in Diabetic Macular Edema (INFINITY)
NCT04418427Phase 2Completed
- Sponsor
- Adverum Biotechnologies
- Start
- May 2020
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of ixoberogene soroparvovec in diabetic macular edema (DME), sponsored by Adverum Biotechnologies. Started May 2020; status: completed.
02
Drugs
ixoberogene soroparvovec
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04418427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418427.